Zinc Inhibits Astrocyte Glutamate Uptake by Activation of Poly(ADP-ribose) Polymerase-1
- 36 Downloads
Several processes by which astrocytes protect neurons during ischemia are now well established. However, less is known about how neurons themselves may influence these processes. Neurons release zinc (Zn2+) from presynaptic terminals during ischemia, seizure, head trauma, and hypoglycemia, and modulate postsynaptic neuronal function. Peak extracellular zinc may reach concentrations as high as 400 µM. Excessive levels of free, ionic zinc can initiate DNA damage and the subsequent activation of poly(ADP-ribose) polymerase 1 (PARP-1), which in turn lead to NAD+ and ATP depletion when DNA damage is extensive. In this study, cultured cortical astrocytes were used to explore the effects of zinc on astrocyte glutamate uptake, an energy-dependent process that is critical for neuron survival. Astrocytes incubated with 100 or 400 µM of zinc for 30 min showed significant decreases in ATP levels and glutamate uptake capacity. These changes were prevented by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-(4-(1-piperidinyl)butoxyl)-1(2H)-isoquinolinone) or PARP-1 gene deletion (PARP-1 KO). These findings suggest that release of Zn2+ from neurons during brain insults could induce PARP-1 activation in astrocytes, leading to impaired glutamate uptake and exacerbation of neuronal injury.
Astrocytes perform several functions that are essential for normal neuron activity, including glutamate uptake, K+ and H+ buffering, water transport, and metabolite exchange (1,2). These astrocyte functions can also influence neuronal survival during ischemia and other brain insults (2). Glutamate homeostasis is a key aspect of astrocyte-neuron interaction during ischemia because of the sensitivity of many neurons to glutamate excitotoxicity (3). Microdialysis studies indicate that extracellular glutamate is maintained at low concentrations in the (viable) ischemic penumbra (4), and failure of astrocyte glutamate uptake may trigger the conversion of ischemic but viable tissue to infarction (5,6). Astrocyte glutamate uptake is accomplished by Na+-dependent transporters (7,8). These transporters move glutamate into astrocytes against a steep concentration gradient by coupling glutamate translocation to the transmembrane Na+, K+, and voltage gradients. These gradients are in turn maintained by membrane Na+/K+ ATPase activity, such that glutamate uptake is ultimately ATP dependent.
While the importance of glutamate uptake and other astrocyte processes is well established, little is known about how neurons themselves may affect this process. The present study explores a mechanism by which neurons may activate astrocyte poly(ADP-ribose) polymerase 1 (PARP-1), thus impairing energy metabolism and glutamate uptake in these cells. PARP activity is shared by a family of enzymes, of which PARP-1 is the most abundant and well characterized (9,10). When activated by DNA strand breaks or kinks, PARP-1 consumes NAD+ to form poly(ADP-ribose) polymers on several acceptor proteins, including histones, DNA polymerase, and DNA ligases (9,11,12). This process appears to facilitate DNA repair; however, excessive PARP-1 activation results in NAD+ and ATP depletion when DNA damage is extensive (10,13,14). Because glutamate uptake requires ATP, it follows that extensive PARP-1 activation in astrocytes could impair glutamate uptake.
Zinc (as Zn2+) leads to PARP-1 activation, probably as a result of increased production of reactive oxygen species in the presence of elevated Zn2+ (15, 16, 17, 18, 19). Neurons release Zn2+ from presynaptic terminals during pathological conditions such as ischemia, seizure, brain trauma, and hypoglycemia (20, 21, 22, 23, 24, 25, 26, 27). In those conditions extracellular Zn2+ concentration may reach 100–400 µM (28, 29, 30, 31, 32), although direct measurements of brain extracellular Zn2+ have not confirmed elevations to this level (33).
The present study examines the effect of Zn2+ elevations on ATP levels and glutamate uptake in cultured astrocytes. We show that Zn2+ can inhibit glutamate uptake in mouse cortical astrocytes by PARP-1 activation and subsequent ATP depletion, and that this effect is attenuated by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-[4-(1-piperidinyl) butoxyl]-1(2H)-isoquinolinone) and by PARP-1 gene deficiency.
Methods and Materials
The studies were performed in accordance with protocols approved by the animal studies committee of the San Francisco Veterans Affairs Medical Center. Reagents were purchased from Sigma Chemical Co (St. Louis, MO, USA) except where noted.
Wild-type astrocyte cultures were prepared from cortices of one-day-old Swiss-Webster mice (Simonsen, Gilroy, CA, USA) as described previously (34,35) and plated into 24-well Falcon culture plates. The PARP-1−/− mice were the 129S Adprt1tm1Zqw strain obtained from Jackson Laboratory (Bar Harbor, ME, USA) and originally developed by Wang et al. (36). The wild-type and PARP-1−/− cortices were harvested, freed of meninges, dissociated with papain digestion (with DNase) and subsequent trituration, and plated on 24-well Falcon culture plates or glass coverslips. Cells were treated for 48 h with 20 µM cytosine arabinoside at confluence (12–15 d in vitro) to prevent microglial proliferation. This medium was replaced with Eagle’s minimal essential medium containing 5 mM glucose supplemented with 5% fetal bovine serum (HyClone, Logan, UT, USA), 2mM glutamine, 100 nM sodium selenate, and 200 nM ±-tocopherol. The astrocyte cultures were used, when confluent, at 20 to 30 d in vitro (37).
Experiments were initiated by replacing the culture medium with artificial cerebrospinal fluid (ACSF). The ACSF contained (in mM) KCl, 3.1; NaCl, 134; CaCl2, 1.2; MgSO4, 1.2; KH2PO4, 0.25; NaHCO3, 15.7; and glucose, 2. The pH was adjusted to 7.2 while the solution was equilibrated with 5% CO2 at 37 °C. Osmolarity was verified at 290–310 mOsm with a Wescor vapor pressure osmometer (Logan, UT, USA). Zinc and PARP inhibitors were added from concentrated stocks prepared in ACSF immediately before use and adjusted to pH 7.2 when necessary. An exposure to Zn2+ (ZnCl2) was performed at 37 °C in a 5% CO2 atmosphere. Thirty minutes of exposure to 100 or 400 µM Zn2+ (as ZnCl2) was performed in ACSF. After the exposure, cultures were washed two times with ACSF and were placed back into the incubator. When used, 1 mM of benzamide or 25 µM of DPQ was added to the medium one hour before and during the Zn2+ exposure. Cultures were then maintained in ACSF until biochemical studies were performed.
For ATP assays, cells were lysed in boiling buffer containing 100 mM Tris and 4 mM EDTA, pH 7.75. Fifty milliliters of cell lysates were mixed with 50-mL aliquots of luciferase/luciferin mixture provided with an ATP bioluminescence assay kit (Roche Diagnostics GmbH, Mannheim, Germany), and photon emission was detected with a luminometer. ATP concentrations were calibrated against ATP standards and expressed as nanomoles per milligram of protein.
Glutamate uptake was measured as described previously (38) with minor modifications. Assays were initiated by replacing the culture medium with ACSF. After a 20-min preincubation in this medium, each culture well received 1.67 µCi/mL L-[14C(U)]glutamate plus unlabeled glutamate to achieve a total glutamate concentration of 100 µM. Uptake was terminated after a 7-min incubation at 37 °C by two washes in ice-cold Hank’s balanced salt solution, followed immediately by cell lysis in 0.1N NaOH. Aliquots were divided for scintillation counting and protein determinations.
Cell death determinations
Astrocyte death was quantified by measuring lactate dehydrogenase (LDH) activity in cell lysates harvested 24 h after Zn2+ exposures. Percentage cell death was calculated by normalizing the LDH values to LDH activity measured in lysates from control (wash only) culture wells (38,39).
All data are presented as means ± SEM and were assessed by analysis of variance (ANOVA) followed by the Bonferroni multiple comparisons test, as post-hoc comparison, for differences between selected pairs of groups. P values less than 0.05 were considered statistically significant.
Zn2+ Inhibits Uptake of Glutamate into Cultured Mouse Astrocytes
PARP Inhibitors and PARP-1 Gene Deletion Prevent Zn2+-Induced Astrocyte Glutamate Uptake Inhibition
Zinc-Induced Glutamate Uptake Inhibition is Not Reversed by Subsequent Addition of a Zinc Chelator
Zn2+ Reduces Both Astrocyte ATP Levels and ATP/ADP Ratios
Zinc-induced inhibition of glutamate uptake is not due to membrane disruption
Zn2+ contributes to neuronal death in several conditions, including stroke, epilepsy, head trauma, and hypoglycemia, and intracerebroventricular administration of the zinc chelator CaEDTA reduces neuronal death (20, 21, 22, 23, 24, 25, 26, 27). It is generally assumed that zinc-induced neurotoxicity in these settings results from direct effects of zinc on the neurons. The present studies suggest an additional or alternative mechanism: zinc released from neurons may induce failure of astrocyte glutamate uptake through a mechanism involving PARP-1 activation and energy failure. The resulting increase in extracellular glutamate levels would be expected to contribute to neuronal demise, and activation of neuronal AMPA/kainate receptors could in turn stimulate additional Zn2+ release (18).
Astrocytes express both EAAT1 and EAAT2 glutamate transporter subtypes, with EAAT2 being responsible for the vast majority of glutamate uptake in most brain structures (8). Zn2+ has been previously reported to modulate glutamate uptake through direct effects on EAAT1 but not EAAT2 (30,42). Several lines of evidence argue that the inhibitory effect of Zn2+ on glutamate uptake observed in the present studies cannot be attributed to a direct effect of Zn2+ on glutamate transporters. First, the effect of Zn2+ incubations was delayed in onset and reached maximal effect 3 hours after washout of Zn2+ from the culture medium. Moreover, the uptake inhibition was not reversed by the addition of the very high affinity Zn2+ chelator, CaEDTA thereby excluding an effect mediated by residual Zn2+ bound to glutamate transporters or other cell membrane components. By contrast, the effect of Zn2+ on glutamate uptake was markedly attenuated both by pharmacological PARP inhibitors and by PARP-1 gene deletion.
The roughly parallel time course of glutamate uptake failure (see Figure 1) and ATP depletion (see Figure 4) further suggest a causative role for PARP-1 activation in the zinc-induced glutamate uptake failure. ATP-dependent processes are sensitive both to absolute ATP concentrations and the ATP/ADP ratio. Here, both of these measures declined after Zn2+ exposure, and these declines were blocked by PARP-1 gene deficiency. Consumption of cytosolic NAD+ by PARP-1 leads to a fall in the ATP/ADP ratio by impairing glycolysis and, indirectly, by impairing respiration (37,43,44) In addition, de novo synthesis of NAD+ is stimulated by NAD+ consumption and leads to depletion of the total ATP and adenylate pools (45). Thus reductions in both the ATP/ADP ratio and total ATP levels occur with extensive PARP-1 activation, and both may contribute to impaired glutamate uptake.
An unresolved question is which events may link the increased intracellular Zn2+ levels to increased PARP-1 activity. Possible candidate mediators are reactive oxygen species (ROS) such as superoxide ion, nitric oxide (NO), and peroxynitrite. In fact, several studies have previously reported that Zn2+ overload results in elevated intracellular levels of ROS in a PKC- and NADPH oxidase-dependent manner (16,46), suggesting that ROS generation may contribute to Zn2+-induced PARP-1 activation. NO, produced by NO synthases (NOS), is a well-established mediator of neuronal cell death in a variety of models of neuronal injury (47) in which Zn2+-induced cell death plays a prominent role (20,21,23,25).
Zn2+, released by neurons into the synapse and surrounding extracellular space during ischemia and other insults, may result in free Zn2+ concentrations of up to 100–400 µM in some brain regions (30, 31, 32). These concentrations are comparable to the levels of Zn2+ observed in the present studies to inhibit glutamate uptake. It should be noted, however, that there are several uncertainties regarding the extrapolation of these cell culture findings to the in vivo setting. First, protein binding of Zn2+ in vivo may lower true free Zn2+ activity (48). Second, a recent study using fluorescent indicators of free Zn2+ showed the extracellular levels achieved during ischemia to be much lower than the estimated maximal values (33). Third, it is possible that Zn2+ could have direct effects on neurons at concentrations well below those that cause impaired astrocyte glutamate uptake. On the other hand, Zn2+ released from intracellular protein binding sites may also contribute to Zn2+-mediated cell injury (49,50). Given these considerations, the present results indicate a potential mechanism by which neuronal Zn2+ release could lead to impaired astrocyte function and further neuronal injury, but additional studies will be required to confirm this process in vivo.
This work was supported by the Department of Veterans Affairs and by the National Institutes of Health grant RO1 NS41421 (R.A.S.). We thank Elizabeth Gum, Jennifer Bergher, and Jillian Silva for expert technical assistance.